Urology Times, Digital Edition, December 2010

"Overall, the take-home message is that in patients with BCG-unresponsive non–muscle invasive bladder cancer, you can consider nadofaragene as an option among those that are available for treating these patients," said Vikram Narayan, MD.

Experts discuss overactive bladder and the impacts on quality of life, distinguishing OAB from BPH, and how a delayed diagnosis can worsen symptoms.

"We found that the majority of malpractice claims were filed in response to delayed diagnosis or treatment and no cases were filed in response to surveillance practices or surgical techniques," said Adri M. Durant, MD.

In this episode of Speaking of Urology, former MLB player Dave Winfield shares lessons he’s learned throughout his professional baseball career and his work in philanthropy.

The priority review decision is based on results of the phase 3 NIAGARA study (NCT03732677).

As centrally assessed, the CR rate was 83.5% (95% CI, 73.9-90.7); the CR rate was 85.9% (95% CI, 76.6-92.5) per investigator assessment.